Repros in the News

All Releases

View Summary Repros Therapeutics Inc.(R) Reports Second Quarter 2013 Financial Results

Aug 7, 2013

PDF 28.6 KB Add to Briefcase
View Summary Repros Seeks to Affirm Its Intellectual Property Rights in Androxal(R)

Aug 5, 2013

PDF 21.2 KB Add to Briefcase
View Summary Repros Announces Formation of Androxal(R) Clinical and Commercial Advisory Board

Jul 9, 2013

PDF 22.0 KB Add to Briefcase
View Summary Repros Therapeutics Inc.(R) Announces the Closing of Public Offering of Common Stock

Jun 25, 2013

PDF 22.6 KB Add to Briefcase
View Summary Repros Therapeutics Inc.(R) Announces Pricing of Public Offering of Common Stock

Jun 19, 2013

PDF 23.7 KB Add to Briefcase
View Summary Repros Therapeutics Inc.(R) Announces Proposed Public Offering of Common Stock

Jun 17, 2013

PDF 23.9 KB Add to Briefcase
View Summary Repros to Webcast Investor and Analyst Day on June 6th

Jun 3, 2013

PDF 24.5 KB Add to Briefcase
View Summary FDA Recommends Running Phase 2b Trial of Proellex(R)-V in the Treatment of Severe Menstrual Bleeding Associated With Uterine Fibroids

May 22, 2013

PDF 20.0 KB Add to Briefcase
View Summary Repros Therapeutics Inc.(R) Reports First Quarter 2013 Financial Results

May 10, 2013

PDF 22.8 KB Add to Briefcase
View Summary Repros Reports Second Pivotal Androxal(R) Study Fully Enrolled Ahead of Schedule

May 2, 2013

PDF 20.9 KB Add to Briefcase
View Summary Repros' Proellex(R) in Breast Cancer Phase 2 Study in Collaboration With Northwestern University

Apr 29, 2013

PDF 23.1 KB Add to Briefcase
View Summary Repros to Present at the Bank of America Merrill Lynch 2013 Health Care Conference

Apr 29, 2013

PDF 21.4 KB Add to Briefcase
View Summary Repros Reports Issuance of Two Additional U.S. Androxal(R) Patents

Apr 10, 2013

PDF 22.9 KB Add to Briefcase
View Summary Repros Reports Both Primary Endpoints Successfully Met in First Pivotal Study of Androxal®

Mar 27, 2013

PDF 61.2 KB Add to Briefcase
View Summary American Urological Association (AUA) Accepts Androxal® Versus Topical Gel Comparative Study for Podium Presentation at Annual Meeting

Mar 25, 2013

PDF 13.3 KB Add to Briefcase
View Summary Repros Therapeutics Inc.® Reports Fourth Quarter and Year End 2012 Financial Results

Mar 18, 2013

PDF 15.0 KB Add to Briefcase
View Summary FDA Grants Repros An End of Phase 2 Meeting in Late May to Discuss Proellex®-V Phase 3 Study Design

Feb 28, 2013

PDF 11.9 KB Add to Briefcase
View Summary Repros Reports FDA Recommends Pivotal Study ZA-301 of Androxal® to be Completed as Originally Planned

Feb 21, 2013

PDF 12.8 KB Add to Briefcase
View Summary Repros Therapeutics Corporate Update

Feb 11, 2013

PDF 14.9 KB Add to Briefcase
View Summary Repros Updates Guidance for Top Line Results from First Pivotal Androxal® Study to Q3 2013

Jan 28, 2013

PDF 14.1 KB Add to Briefcase
Showing 81-100 of 195 Page: 1 2 3 4 5 6 7 8 9 10  Previous 20 | Next 20
Add to Briefcase = add release to Briefcase
2408 Timberloch Place, B-7
The Woodlands, Texas 77380
281-719-3400
281-719-3446 fax